Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 6/20 | 0.41 |
| ▸ | RXRA | P19793 | 8/20 | 0.41 |
| ▸ | RXRB | P28702 | 8/20 | 0.41 |
| ▸ | RXRG | P48443 | 5/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | BAD | Q92934 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656913 | 0.84 | LMNA (0.45) | LMNASMN1; SMN2IDO1RXRARXRB | |
| SCHEMBL31312989 | 0.83 | BCL2L1 (0.54) | SMN1; SMN2IDO1RXRARXRBRXRG | |
| SCHEMBL5660017 | 0.81 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2IDO1RXRARXRB | |
| SCHEMBL5659543 | 0.80 | RXRB (0.59) | LMNASMN1; SMN2IDO1RXRARXRB | |
| SCHEMBL30306120 | 0.79 | BCL2L1 (0.50) | LMNASMN1; SMN2RXRARXRBRXRG | |
| SCHEMBL8483842 | 0.79 | BCL2L1 (0.50) | LMNASMN1; SMN2RXRARXRBRXRG | |
| SCHEMBL19249593 | 0.78 | BCL2L1 (0.48) | LMNASMN1; SMN2RXRARXRBRXRG | |
| SCHEMBL4440731 | 0.77 | SLC6A4 (0.42) | TSHR | |
| SCHEMBL3150959 | 0.76 | BCL2L1 (0.43) | LMNASMN1; SMN2BCL2L1BADTSHR | |
| SCHEMBL29292716 | 0.76 | MEN1 (0.41) | IDO1RXRARXRBRXRGBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262309-B2 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) | 2007-08-28 | — | — | US | disclosed |
| EP-1492795-B1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2005-11-16 | — | — | EP | disclosed |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.D.D. (HR) | 2005-06-23 | — | — | US | disclosed |
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | LMNA 3718/4885SMN1; SMN2 3760/4885IDO1 90/4885 |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | LMNA 2813/4885SMN1; SMN2 3809/4885IDO1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.